Updated:
STAAR Surgical
STAAR Surgical, led by CEO Thomas Frinzi, manufactures implantable Collamer lenses as an alternative to LASIK, with operations in over 75 countries.
STAAR Surgical
STAAR Surgical was founded in 1982 as a developer of innovative ophthalmic implants, but the modern era began with Thomas Frinzi's appointment as president and CEO a decade ago. The company's wealth and market position are tied entirely to operational revenue from one flagship product category: the Visian Implantable Collamer Lens, known as the ICL. Unlike LASIK, which reshapes the cornea, the ICL is implanted behind the iris to correct refractive errors while keeping the cornea intact (per the firm's official communications). This structural distinction is the foundation of its economic existence. Investment deployment is manufacturing and inventory, not financial capital. The firm runs a direct sales and marketing engine across three main hubs — Lake Forest, California; Nidau, Switzerland; and Tokyo — to reach refractive surgeons and hospitals. Its core market is Asia Pacific, where high myopia prevalence makes the ICL the preferred option over corneal procedures. Japan, China, and South Korea collectively drive the majority of revenue. The supply chain is concentrated: lens manufacturing occurs exclusively at the Swiss facility, which ships finished units to distribution centers worldwide. The firm holds a portfolio of over 200 US and international patents on the Collamer material and ICL design, serving as a defensive moat against would-be generic competitors. The company operates as a publicly listed entity on the Nasdaq, with roughly 800 employees as of late 2023. The organizational structure is flat for a medical-device manufacturer — R&D, manufacturing, and commercial teams report directly to Frinzi with no intermediate holding vehicles or family-office overlays. A secondary operational event reshaped its compliance posture in 2020, when the FDA issued a warning letter over promotional claims and subsequent follow-up actions led the agency to close out the matter with no financial penalty. May 2024: Frinzi launched a new lens-loading device, the EVO ICL, designed to reduce surgeon assembly time on-site, marking the firm's most visible product update in years. Structurally, STAAR is a pure-play independent in a consolidating ophthalmology industry — it is neither a division of a broader pharmaceutical conglomerate nor a private-equity roll-up. Most competitors, like Alcon and Johnson & Johnson Vision, wrap their ophthalmic lenses into sprawling healthcare portfolios that cross-subsidize product lines. STAAR cannot do that. Its survival depends entirely on winning refractive surgery volume quarter over quarter, which forces a discipline around surgeon training and post-market surveillance that larger rivals outsource to third-party distributors.
General information
Firm type
Asset Manager
Year founded
1982
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Lake Forest
Corporate office
Lake Forest, CA, United States
Additional offices
Nidau, Switzerland · Tokyo, Japan
Principals
Thomas G. Frinzi
President and CEO
Stephen C. Farrell
Chairman of the Board
Sector focus
Frequently asked questions
Who runs investment and operational decisions at STAAR Surgical?
Thomas G. Frinzi has served as President and CEO since 2013, overseeing both strategic direction and day-to-day execution. The board, chaired by Stephen C. Farrell, governs capital allocation, but there is no separate family office or investment committee structure. All deployment decisions flow through standard public-company governance and the executive leadership team.
How does STAAR Surgical generate its capital for reinvestment?
STAAR is a publicly traded operating company, not an allocator of outside funds. It generates capital entirely through sales of implantable Collamer lenses to refractive surgeons and hospitals. Revenue is plowed back into manufacturing upgrades in Switzerland, clinical trials for new lens models, and expansion of direct-sales teams in Asia Pacific, which remains its dominant commercial territory.
Is STAAR Surgical structured as a family office or a traditional medical device company?
It is a traditional, publicly listed medical device company trading on Nasdaq under the ticker STAA. There is no underlying family wealth, multi-generational transfer structure, or separate investment vehicle. It is a single-product-line manufacturer competing in the refractive surgery market alongside much larger diversified healthcare conglomerates.
What distinguishes an ICL from LASIK, and why does that matter for the company's posture?
The implantable Collamer lens is surgically placed behind the iris and in front of the natural lens to correct myopia without removing corneal tissue. This makes it reversible and suitable for patients with thin corneas or severe myopia who are poor LASIK candidates. That narrow clinical niche creates an economic moat: STAAR is one of very few manufacturers globally with FDA-approved phakic intraocular lenses, and its Swiss-made Collamer material is proprietary to the firm.
Which geographic markets drive STAAR's revenue?
Asia Pacific accounts for the majority of revenue, with Japan, China, and South Korea as the top three country-level markets. High myopia rates in these populations generate outsized demand for ICL procedures. The United States and Europe represent smaller but growing shares, as regulatory approvals for newer lens models have expanded the addressable surgeon base in those regions.
Does STAAR Surgical maintain philanthropic structures or a foundation?
The firm does not publicly disclose a separate philanthropic foundation or donor-advised vehicle. Its public communications focus on surgeon training programs and ongoing clinical studies rather than charitable grantmaking. Any corporate giving would flow through the public-company budget and standard ESG disclosures.
What is STAAR Surgical's known posture on co-investments or fund commitments?
STAAR Surgical has no known co-investment program or fund-of-funds activity. As a single-product-line manufacturer, it does not operate as an institutional allocator. Its capital deployment is limited to internal R&D, clinical trials, manufacturing scale-up, and commercial infrastructure — none of which involve external GP commitments or direct minority investments in other companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: